KPTI Quote, Financials, Valuation and Earnings

Rocket Pharmaceuticals has a net margin of -78.17% compared to Karyopharm Therapeutics's net margin of --. Karyopharm Therapeutics's return on equity of -- beat Rocket Pharmaceuticals's return on equity of --.

Karyopharm Therapeutics has a consensus price target of $29.25, signalling upside risk potential of 544.27%. On the other hand Rocket Pharmaceuticals has an analysts' consensus of $9.03 which suggests that it could grow by 229.86%. Given that Karyopharm Therapeutics has higher upside potential than Rocket Pharmaceuticals, analysts believe Karyopharm Therapeutics is more attractive than Rocket Pharmaceuticals.

Karyopharm Therapeutics has a beta of 0.230, which suggesting that the stock is 76.987% less volatile than S&P 500. In comparison Rocket Pharmaceuticals has a beta of 0.684, suggesting its less volatile than the S&P 500 by 31.64%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rocket Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Rocket Pharmaceuticals pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30M, which are larger than Rocket Pharmaceuticals quarterly revenues of --. Karyopharm Therapeutics's net income of -$23.5M is higher than Rocket Pharmaceuticals's net income of -$61.3M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Rocket Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.28x versus -- for Rocket Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals has a net margin of -78.17% compared to Karyopharm Therapeutics's net margin of 26.7%. Karyopharm Therapeutics's return on equity of -- beat Regeneron Pharmaceuticals's return on equity of 15.7%.

Karyopharm Therapeutics has a consensus price target of $29.25, signalling upside risk potential of 544.27%. On the other hand Regeneron Pharmaceuticals has an analysts' consensus of $727.21 which suggests that it could grow by 39.13%. Given that Karyopharm Therapeutics has higher upside potential than Regeneron Pharmaceuticals, analysts believe Karyopharm Therapeutics is more attractive than Regeneron Pharmaceuticals.

Karyopharm Therapeutics has a beta of 0.230, which suggesting that the stock is 76.987% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals has a beta of 0.309, suggesting its less volatile than the S&P 500 by 69.074%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals offers a yield of 0.34% to investors and pays a quarterly dividend of $0.88 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Regeneron Pharmaceuticals pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30M, which are smaller than Regeneron Pharmaceuticals quarterly revenues of $3B. Karyopharm Therapeutics's net income of -$23.5M is lower than Regeneron Pharmaceuticals's net income of $808.7M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Regeneron Pharmaceuticals's PE ratio is 13.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.28x versus 4.23x for Regeneron Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -78.17% compared to Karyopharm Therapeutics's net margin of -60.08%. Karyopharm Therapeutics's return on equity of -- beat Sarepta Therapeutics's return on equity of -20.94%.

Karyopharm Therapeutics has a consensus price target of $29.25, signalling upside risk potential of 544.27%. On the other hand Sarepta Therapeutics has an analysts' consensus of $60.25 which suggests that it could grow by 226.81%. Given that Karyopharm Therapeutics has higher upside potential than Sarepta Therapeutics, analysts believe Karyopharm Therapeutics is more attractive than Sarepta Therapeutics.

Karyopharm Therapeutics has a beta of 0.230, which suggesting that the stock is 76.987% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.609, suggesting its less volatile than the S&P 500 by 39.15%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Karyopharm Therapeutics's net income of -$23.5M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.28x versus 1.04x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -78.17% compared to Karyopharm Therapeutics's net margin of 23.33%. Karyopharm Therapeutics's return on equity of -- beat Vertex Pharmaceuticals's return on equity of -6.04%.

Karyopharm Therapeutics has a consensus price target of $29.25, signalling upside risk potential of 544.27%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.12 which suggests that it could grow by 10.91%. Given that Karyopharm Therapeutics has higher upside potential than Vertex Pharmaceuticals, analysts believe Karyopharm Therapeutics is more attractive than Vertex Pharmaceuticals.

Karyopharm Therapeutics has a beta of 0.230, which suggesting that the stock is 76.987% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.415, suggesting its less volatile than the S&P 500 by 58.544%.

Karyopharm Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Karyopharm Therapeutics pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Karyopharm Therapeutics quarterly revenues are $30M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Karyopharm Therapeutics's net income of -$23.5M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, Karyopharm Therapeutics's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Karyopharm Therapeutics is 0.28x versus 10.52x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.